Ver.1.0

Info Sheet for Technical description

No. 0019

Organization

* Mandatoty fields

Name of Organization*	Gaudi Clinical Co., Ltd.	
Address, City, States, Zip, Country*	Neo-Kawai Bldg 10F 4-8-15 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-0023, Japan	
URL	www.gaudi-clinical.co.jp	
Brief Descriptions of Organization* (Approx. 100 words)	Gaudi Clinical is a platform developer for the distribution of regenerative medicine. We establish decentralized logistics network close proximity to medical institutions to optimize transportation. Our contract manufacturing services are offered at appropriate prices, ensuring the production of safe, high-quality cells founded on technologies verified in academia. Beyond cell processing, we provide comprehensive support to medical institutions through regulatory compliance guidance, education and training for healthcare providers, and the systematic collection and analysis of treatment data. Our mission is to "bridge the last mile" in regenerative medicine delivery.	
Contact address	Name*	Hiroyuki Shibata
	Department* / Position	Representative Director, Chief Operating Officer
	E-mail* / TEL	hiroyuki.shibata@gaudi-clinical.co.jp / +81 3 3868 3577

What kind of technology do you want to offer? *

- ☐ **A.** Clinical Development Pipelines → Please see **Sheet【A】**
- ☑ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc. → Please see **Sheet【B】**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet【C】**

  * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☑ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☑ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☑ Series B
- ☐ Series C
- ☐ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☑ Yes	
☐ No	

Filled in by*	Hiroyuki Shibata
Date*	17-Sep-25

Ver.1.0

Sheet【B】 Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc.

Info Sheet for Technical overview

No. B-0019

* Mandatoty fields

Title*

Cell Processing Contracts for Cell Therapies in Japan (ASCs and PRP)

Category*

☐	Facilities	☐	Manufacturing equipment	☐	Inspection equipment
☐	Cells	☐	Culture medium	☐	Reagents
☐	Cell banking	☐	Storage / Container	☐	Logistics
☐	Cell / Viral vector manufacturing technology			☑	CDMO Servicies

Description*

Gaudi Clinical Co., Ltd. has launched contract cell processing services for orthopedic and dental cell therapies under the Act on the Safety of Regenerative Medicine. Our technological strengths can be summarized in three key areas:
1. Academia-derived technology with proven safety
Gaudi Clinical's engineers acquire their expertise through technology transfer from academic developers with extensive experience in each cell processing technology. These techniques are further validated and refined in-house, ensuring strong capabilities in both manufacturing processes and quality control systems.
2. Decentralized logistics network for efficient delivery and comprehensive support for medical institutions
We establish cell preparation centers in close proximity to medical institutions to ensure timely delivery of cells. These centers are staffed with specialized personnel who provide comprehensive support to medical institutions, helping to alleviate their workloads in logistics, regulatory compliance, and data management.
3. Advancing therapeutic development through data collection
We plan to support registry studies led by the developers of the technologies, who will serve as principal investigator (PIs). By employing standardized manufacturing protocols, clinical data on cell therapies can be systematically collected. The accumulated findings are expected to contribute to the development of safer, more effective, and optimized treatments.

Filled in by*	Hiroyuki Shibata
Date*	2025/9/17